Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma. - Wikidata - wikimedia - TriplyDB

Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma.

Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma.

http://www.wikidata.org/entity/Q37095230

about

Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.The role of tumor microenvironment in resistance to anti-angiogenic therapy.

P2860

Q33868524-E5A235C2-2443-4F61-B640-D4DCD03B36BA Q47773621-8CFA684C-5E3D-4A44-B50C-6B1F06A2D7B6 Q52645823-A8F773AD-0A9F-4424-B898-ABE8F433C64B

P2860

Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma.

http://www.wikidata.org/entity/Q37095230

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting Bone Marrow to Poten ...... t Model of Human Glioblastoma.

@en

Targeting Bone Marrow to Poten ...... t Model of Human Glioblastoma.

@nl

type

label

Targeting Bone Marrow to Poten ...... t Model of Human Glioblastoma.

@en

Targeting Bone Marrow to Poten ...... t Model of Human Glioblastoma.

@nl

prefLabel

Targeting Bone Marrow to Poten ...... t Model of Human Glioblastoma.

@en

Targeting Bone Marrow to Poten ...... t Model of Human Glioblastoma.

@nl

P1433

Q37095230-9888D9A8-67B7-4FE7-B936-A139E02E8777

P1476

Q37095230-A21D9194-A364-4BF4-BA37-72997EDCBB28

P2093

Q37095230-16DD5729-3391-46E1-85AF-D3FDE2A135DE

Q37095230-272FEB86-6804-4E32-916E-5BAAADB28E2B

Q37095230-6B7F9C60-D24E-4B95-9BA9-DF4AE2E2C491

Q37095230-8DC156AC-BC47-4081-BBAF-974034FC61EF

Q37095230-BABD00F6-A48D-466B-BCD0-A108E0C9A8FF

Q37095230-BE156CC9-4ABC-4A2E-BBAA-91FC2021A61E

Q37095230-C16785E5-8404-4C62-86ED-CCACAD219EA0

Q37095230-C82317D8-B126-4261-9547-A15B22E3080E

Q37095230-D536887F-D97A-4160-B49E-1CC7610EE793

Q37095230-E05320B9-D974-45B6-94DD-61E74786BFED

P2860

Q37095230-056CFAFA-62BE-4693-BDD8-C9E9554B4179

Q37095230-07954A48-5BBF-4E4A-BA3D-CE1CA17EEA7F

Q37095230-0824C5E7-972E-4A72-815B-B457F7AB5E9C

Q37095230-088290C8-B807-4B5E-B968-5236B28AA8AD

Q37095230-0BD4A93B-3E54-46D9-8278-9EDE763A3385

Q37095230-0E3FF20B-5B16-4917-8BE2-2D28CCCFBD14

Q37095230-1BD69A85-7813-449D-96E5-5868FFF34E0B

Q37095230-1F8702E5-B6E4-4194-BB9C-34CDE3A97221

Q37095230-24627968-7F98-407B-AC9A-08B387F2B4CF

Q37095230-2CC621DF-297B-4F4E-96B6-54CFF08EA297

P304

Q37095230-5D1AD2BF-D57F-42CE-8A04-E661E44931A3

P31

Q37095230-CEC9B925-4136-42C8-B69A-0FCE49525938

P356

Q37095230-AA4BA5EE-BFE9-4362-8F39-220EF722FE95

P433

Q37095230-2A32810D-BDC9-41E6-B90B-DDBBE5FA4D56

P478

Q37095230-B9E9D900-9446-4C3B-B594-2F1FBB017A5E

P577

Q37095230-50D904B4-6BC9-4F05-9052-3B0EF25A6AE5

P698

Q37095230-5674C600-D2E8-4A60-A732-0171ECBACB51

P932

Q37095230-AB74B981-3706-4820-982D-A92F7A5103C6

P356

IJCR.2016.69.81

P1433

International journal of cancer research

P1476

Targeting Bone Marrow to Poten ...... t Model of Human Glioblastoma.

@en

P2093

A Iskander

http://www.w3.org/2001/XMLSchema#string

A S Arbab

http://www.w3.org/2001/XMLSchema#string

A Shankar

http://www.w3.org/2001/XMLSchema#string

B R Achyut

http://www.w3.org/2001/XMLSchema#string

H Bagher-Ebadian

http://www.w3.org/2001/XMLSchema#string

K Angara

http://www.w3.org/2001/XMLSchema#string

M Alsulami

http://www.w3.org/2001/XMLSchema#string

M Jain

http://www.w3.org/2001/XMLSchema#string

R Ara

http://www.w3.org/2001/XMLSchema#string

S A Arbab

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand

Model selection in measures of vascular parameters using dynamic contrast-enhanced MRI: experimental and clinical applications

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Bone marrow suppression induced by high dose valproic acid

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.

Sodium valproate and bone marrow suppression.

P304

69-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3923/IJCR.2016.69.81

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27429653

http://www.w3.org/2001/XMLSchema#string

P932

4945124

http://www.w3.org/2001/XMLSchema#string